{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:04:17Z","timestamp":1793747057203,"version":"4.6.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004092","name":"Kuopion Yliopistollinen Sairaala","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004092","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007083","name":"Orionin Tutkimuss\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Vascular endothelial growth factors (VEGFs) are major regulators of intratumoral angiogenesis in ovarian cancer (OVCA). Overexpression of VEGFs is associated with increased tumor growth and metastatic tendency and VEGF-targeting therapies are thus considered as potential treatments for OVCA. Here, we examined the antiangiogenic and antitumoral effects on OVCA of adeno-associated virus 8 (AAV8)-mediated expression of soluble VEGF receptors (sVEGFRs) sVEGFR2 and sVEGFR3 together with paclitaxel and carboplatin chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Immunodeficient mice were inoculated with human OVCA cell line SKOV-3m. Development of tumors was confirmed with magnetic resonance imaging (MRI) and mice were treated with gene therapy and paclitaxel and carboplatin chemotherapy. The study groups included (I) non-treated control group, (II) blank control vector AAV8-CMV, (III) AAV8-CMV with chemotherapy, (IV) AAV8-sVEGFR2, (V) AAV8-sVEGFR3, (VI) AAV8-sVEGFR2 and AAV8-sVEGFR3, and (VII) AAV8-sVEGFR2 and AAV8-sVEGFR3 with chemotherapy. Antiangiogenic and antitumoral effects were evaluated with immunohistochemical stainings and serial MRI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Reduced intratumoral angiogenesis was observed in all antiangiogenic gene therapy groups. The combined use of AAV8-sVEGFR2 and AAV8-sVEGFR3 with chemotherapy suppressed ascites fluid formation and tumor growth, thus improving the overall survival of mice. Antitumoral effect was mainly caused by AAV8-sVEGFR2 while the benefits of AAV8-sVEGFR3 and chemotherapy were less prominent.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Combined use of the AAV8-sVEGFR2 and AAV8-sVEGFR3 with chemotherapy reduces intratumoral angiogenesis and tumor growth in OVCA mouse model. Results provide preclinical proof-of-concept for the use of soluble decoy VEGFRs and especially the AAV8-sVEGFR2 in the treatment of OVCA.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.1018208","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T11:42:25Z","timestamp":1670499745000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["AAV8-mediated sVEGFR2 and sVEGFR3 gene therapy combined with chemotherapy reduces the growth and microvasculature of human ovarian cancer and prolongs the survival in mice"],"prefix":"10.3389","volume":"9","author":[{"given":"Anni","family":"Kujala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Valkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Sallinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Tuppurainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Laakso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Yl\u00e4-Herttuala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Liimatainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jouni","family":"Kujala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Jokelainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reijo","family":"Sironen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarit","family":"Anttila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seppo","family":"Yl\u00e4-Herttuala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3389\/fonc.2019.00639","article-title":"Real-world impact of survival by period of diagnosis in epithelial ovarian cancer between 1990 and 2014.","volume":"9","author":"Wu","year":"2019","journal-title":"Front Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"7018","DOI":"10.1002\/cam4.2560","article-title":"Ovarian cancer: current status and strategies for improving therapeutic outcomes.","volume":"8","author":"Chandra","year":"2019","journal-title":"Cancer Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ceb.2008.12.012","article-title":"VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.","volume":"21","author":"Lohela","year":"2009","journal-title":"Curr Opin Cell Biol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.molmed.2011.01.015","article-title":"VEGF and angiopoietin signaling in tumor angiogenesis and metastasis.","volume":"17","author":"Saharinen","year":"2011","journal-title":"Trends Mol Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/mt.2008.258","article-title":"Antiangiogenic gene therapy with soluble VEGFR-1, \u20132, and \u20133 reduces the growth of solid human ovarian carcinoma in mice.","volume":"17","author":"Sallinen","year":"2009","journal-title":"Mol Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1002\/ijc.27495","article-title":"Antiangiogenic gene therapy with soluble VEGF-receptors \u20131, \u20132 and \u20133 together with paclitaxel prolongs survival of mice with human ovarian carcinoma.","volume":"131","author":"Sopo","year":"2012","journal-title":"Int J Cancer."},{"key":"B8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4172\/2157-7412.1000171","article-title":"Functional MRI measurements to predict early adenoviral gene therapy response in ovarian cancer mouse model.","volume":"4","author":"Tuppurainen","year":"2013","journal-title":"J Genet Syndr Gene Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/IGC.0000000000000973","article-title":"Combined gene therapy using AdsVEGFR2 and AdsTie2 with chemotherapy reduces the growth of human ovarian cancer and formation of ascites in mice.","volume":"27","author":"Tuppurainen","year":"2017","journal-title":"Int J Gynecol Cancer."},{"key":"B10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jconrel.2016.01.001","article-title":"Adeno-associated virus (AAV) vectors in cancer gene therapy.","volume":"240","author":"Santiago-Ortiz","year":"2016","journal-title":"J Controlled Release."},{"key":"B11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10555-014-9538-9","article-title":"Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.","volume":"34","author":"Choi","year":"2015","journal-title":"Cancer Metastasis Rev."},{"key":"B12","first-page":"1624","article-title":"Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment.","volume":"6","author":"Ai","year":"2016","journal-title":"Am J Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ygyno.2006.03.030","article-title":"A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up.","volume":"103","author":"Sallinen","year":"2006","journal-title":"Gynecol Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3389\/fcell.2017.00101","article-title":"Therapy for cancer: strategy of combining anti-angiogenic and target therapies.","volume":"5","author":"Comunanza","year":"2017","journal-title":"Front Cell Dev Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3390\/cells11040650","article-title":"Recent advances in ovarian cancer: therapeutic strategies, potential biomarkers, and technological improvements.","volume":"2022","author":"Akter","year":"2022","journal-title":"Cells."},{"key":"B16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/labinvest.2010.52","article-title":"Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells.","volume":"90","author":"Adham","year":"2010","journal-title":"Lab Investig."},{"key":"B17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12943-016-0497-3","article-title":"Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?","volume":"15","author":"Bekes","year":"2016","journal-title":"Mol Cancer."},{"key":"B18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3389\/fonc.2018.00595","article-title":"Ascites volumes and the ovarian cancer microenvironment.","volume":"8","author":"Penet","year":"2018","journal-title":"Front Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1148\/radiol.2019190545","article-title":"Diffusion-weighted MRI in advanced epithelial ovarian cancer: apparent diffusion coefficient as a response marker.","volume":"293","author":"Winfield","year":"2019","journal-title":"Radiology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.omtm.2019.08.015","article-title":"Clinical considerations for capsid choice in the development of liver-targeted AAV-based gene transfer.","volume":"15","author":"Pipe","year":"2019","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1172\/JCI79213","article-title":"Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy.","volume":"125","author":"Chandler","year":"2015","journal-title":"J Clin Investig."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1018208\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T11:42:31Z","timestamp":1670499751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1018208\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":21,"alternative-id":["10.3389\/fmed.2022.1018208"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1018208","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"article-number":"1018208"}}